<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016951</url>
  </required_header>
  <id_info>
    <org_study_id>D1882C00002</org_study_id>
    <secondary_id>EudraCT number: 2009-015645-23</secondary_id>
    <nct_id>NCT01016951</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in
      healthy male and female subjects and COPD patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped since it was considered that one of the pre-defined stopping criterion was met.
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements (ECG's, Telemetry, Pulse, Blood Pressure, Safety Laboratory and Adverse Events)</measure>
    <time_frame>Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics samples for AZD9164</measure>
    <time_frame>PK sampling during the residential period and intense PK sampling day 1 and 15 in healthy and day 13 in COPD patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of PD effects</measure>
    <time_frame>Spirometry at screening and during the residential stay</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9164</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9164 Turbuhaler®</intervention_name>
    <description>Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.
The COPD patients will receive a dose of 1000 µg.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Turbuhaler®</intervention_name>
    <description>Dry powder for inhalation via Turbuhaler, MAD</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female, age 18-45, COPD patients &gt; 40 years

          -  Healthy subjects and COPD patients; Provision of signed and dated, written informed
             consent prior to any study specific procedures

          -  Healthy subjects; Females must have a negative pregnancy test, must not be lactating
             and must be of non-child-bearing potential, by the following criteria: - irreversible
             surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral
             salpingectomy

          -  COPD patients; Females must have a negative pregnancy test, must not be lactating and
             must be of non-child-bearing potential, by the following criteria: Post menopausal.
             Woman below 50 years old will be considered post menopausal if they have been
             amenorrheic for 12 months or more following cessation of exogenous hormonal
             treatments, and with LH and FSH levels in the post menopausal range. Women over 50
             years of age will be considered post menopausal if they have been amenorrheic for 12
             months or more following cessation of all exogenous hormonal treatment. - irreversible
             surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral
             salpingectomy

          -  Healthy subjects; Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and
             weigh at least 50 kg and no more than 100 kg

          -  COPD patients; Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and
             weigh at least 50 kg and no more than 100 kg

        Exclusion Criteria:

          -  Healthy subjects; Any clinically significant disease or disorder which, in the opinion
             of the investigator, may either put the subject at risk because of participation in
             the study, or influence the results of the subject's ability to participate in the
             study

          -  COPD patients; Any clinically significant disease or disorder (other than COPD) which,
             in the opinion of the investigator, may either put the subject at risk because of
             participation in the study, or influence the results of the subject's ability to
             participate in the study

          -  Healthy subject and COPD patients; Any clinically significant abnormalities in
             clinical chemistry, haematology, urinalysis or physical examination results as judged
             by the investigator

          -  Healthy subject and COPD patients; Any clinically important abnormalities in rhythm,
             conduction or morphology of resting ECG that may interfere with the interpretation of
             QTc interval changes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aslak Rautio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Hermelinen AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Carin Jorup MD, Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Safety study</keyword>
  <keyword>AZD9164</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

